Drug Trial Radar · NCT02714595
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Last checked: Nov 20, 2026Latest source record: Jan 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Sep 7, 2016
Primary completion
Apr 1, 2019
Study completion Apr 22, 2019
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Mar 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
Conditions
- Healthcare-associated Pneumonia (HCAP)
- Bloodstream Infections (BSI)
- Hospital Acquired Pneumonia (HAP)
- Complicated Urinary Tract Infection (cUTI)
- Sepsis
- Ventilator Associated Pneumonia (VAP)
Interventions
CefiderocolDrug
2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days, or 2 g every 6 hours for participants with creatinine clearance \>120 mL/min.
Best Available TherapyDrug
Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Clinical Cure at Test of Cure (TOC) in Participants With HAP/VAP/HCAP or BSI/SepsisTime frame: Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21
- Percentage of Participants With Microbiologic Eradication at TOC in Participants With cUTITime frame: Test of cure, defined as 7 days after the end of treatment, equivalent to Study Days 14 to 21
Locations
85 sites in 16 countries. Site status is shown where the registry gives one.
Shionogi Research Site
Hartford, Connecticut
Shionogi Research Site
Newark, Delaware
Shionogi Research Site
Chicago, Illinois
Shionogi Research Site
New Orleans, Louisiana
Shionogi Research Site
Detroit, Michigan
Shionogi Research Site
Pittsburgh, Pennsylvania
Shionogi Research Site
Salvador, Estado de Bahia, Brazil
Shionogi Research Site
Curitiba, Paraná, Brazil
Shionogi Research Site
Passo Fundo, Rio Grande do Sul, Brazil
Shionogi Research Site
Porto Alegre, Rio Grande do Sul, Brazil
Shionogi Research Site
Porto Alegre, Rio Grande do Sul, Brazil
Shionogi Research Site
Santa Maria, Rio Grande do Sul, Brazil
Shionogi Research Site
São José do Rio Preto, São Paulo, Brazil
Shionogi Research Site
São Paulo, São Paulo, Brazil
Shionogi Research Site
Split, Croatia
Shionogi Research Site
Zagreb, Croatia
Shionogi Research Site
Rijeka, Primorje-Gorski Kotar County, Croatia
Shionogi Research Site
La Tronche, Auvergne-Rhône-Alpes, France
Shionogi Research Site
Paris, Île-de-France Region, France
Shionogi Research Site
Berlin, Germany
Shionogi Research Site
Heidelberg, Baden-Wurttemberg, Germany
Shionogi Research Site
Bonn, North Rhine-Westphalia, Germany
Shionogi Research Site
Athens, Attica, Greece
Shionogi Research Site
Athens, Attica, Greece
Shionogi Research Site
Patra, Peloponnese, Greece
Shionogi Research Site
Larissa, Thessaly, Greece
Shionogi Research Site
Larissa, Thessaly, Greece
Shionogi Research Site
Guatemala City, Guatemala
Shionogi Research Site
Hadera, Israel
Shionogi Research Site
Haifa, Israel
Shionogi Research Site
Haifa, Israel
Shionogi Research Site
Holon, Israel
Shionogi Research Site
Jerusalem, Israel
Shionogi Research Site
Beersheba, Beersheba, Israel
Shionogi Research Site
Be’er Ya‘aqov, Rehoboth, Israel
Shionogi Research Site
Tel Aviv, Tel Aviv, Israel
Shionogi Research Site
Tel HaShomer, Tel Aviv, Israel
Shionogi Research Site
Safed, Zefat, Israel
Shionogi Research Site
Milan, Italy
Shionogi Research Site
Milan, Italy
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.